MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
Log in

NYSE:KDMNKadmon Stock Price, Forecast & News

$4.56
-0.03 (-0.65 %)
(As of 05/27/2020 10:34 AM ET)
Add
Compare
Today's Range
$4.32
Now: $4.56
$4.65
50-Day Range
$3.70
MA: $4.36
$4.84
52-Week Range
$1.63
Now: $4.56
$5.50
Volume415,104 shs
Average Volume2.73 million shs
Market Capitalization$729.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.
Read More
Kadmon logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.15 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone833-900-5366

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.09 million
Book Value$0.60 per share

Profitability

Net Income$-61,370,000.00
Net Margins-813.33%

Miscellaneous

Employees116
Market Cap$729.74 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter.

Kadmon (NYSE:KDMN) Frequently Asked Questions

How has Kadmon's stock been impacted by COVID-19 (Coronavirus)?

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KDMN stock has increased by 31.0% and is now trading at $4.56. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kadmon?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon.

When is Kadmon's next earnings date?

Kadmon is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Kadmon.

How were Kadmon's earnings last quarter?

Kadmon Holdings Inc (NYSE:KDMN) released its quarterly earnings data on Thursday, May, 7th. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.05. The business had revenue of $6.74 million for the quarter, compared to analysts' expectations of $0.38 million. Kadmon had a negative net margin of 813.33% and a negative return on equity of 142.79%. View Kadmon's earnings history.

What price target have analysts set for KDMN?

5 analysts have issued 1 year price targets for Kadmon's stock. Their forecasts range from $7.00 to $25.00. On average, they anticipate Kadmon's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price. View analysts' price targets for Kadmon.

Has Kadmon been receiving favorable news coverage?

News stories about KDMN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kadmon earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutKadmon.

Who are some of Kadmon's key competitors?

What other stocks do shareholders of Kadmon own?

Who are Kadmon's key executives?

Kadmon's management team includes the following people:
  • Dr. Harlan W. Waksal, Pres, CEO & Director (Age 66)
  • Mr. Steven Meehan, Exec. VP & CFO (Age 54)
  • Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 51)
  • Ms. Cynthia L. Schwalm, Director (Age 59)
  • Mr. Kyle Carver, Controller & Principal Accounting Officer

When did Kadmon IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What is Kadmon's stock symbol?

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Who are Kadmon's major shareholders?

Kadmon's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (9.82%), Vivo Capital LLC (7.84%), BlackRock Inc. (7.53%), State Street Corp (2.33%), Geode Capital Management LLC (1.41%) and Invesco Ltd. (1.12%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc. View institutional ownership trends for Kadmon.

Which major investors are selling Kadmon stock?

KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Invesco Ltd., Nuveen Asset Management LLC, Ghost Tree Capital LLC, Two Sigma Investments LP, Soleus Capital Management L.P., Telemetry Investments L.L.C., and Acadian Asset Management LLC. View insider buying and selling activity for Kadmon.

Which major investors are buying Kadmon stock?

KDMN stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, Perceptive Advisors LLC, Healthcare of Ontario Pension Plan Trust Fund, and Two Sigma Advisers LP. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc. View insider buying and selling activity for Kadmon.

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $4.56.

How big of a company is Kadmon?

Kadmon has a market capitalization of $729.74 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe.

What is Kadmon's official website?

The official website for Kadmon is www.kadmon.com.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.